Inclusion Criteria:

1. Patients must have: IIIA or IIIB non-small cell lung cancer by radiographic or
surgical staging, excluding: superior sulcus tumors, tumors with associated
atelectasis or obstructive pneumonitis of the entire lung, and tumors with a
malignant pleural effusion.

2. Patients will be included in the study based on the following criteria:

- Patients must be older than 18 years old.

- Patients must have a Zubrod performance status of 0 to 2

- Patients with adequate bone marrow function

- Patients with adequate renal function

- Patients with adequate hepatic function

- Patients of childbearing potential must have a negative serum pregnancy test and
use an effective form of contraception.

- Patients who are suitable for treatment with radical intent using concurrent
chemotherapy and radiation.

- Patients who have signed an approved informed consent and authorization
permitting release of personal health information.

Exclusion Criteria:

1. Disease-Specific Exclusions

- Superior sulcus tumors

- Atelectasis or obstructive pneumonitis of the entire lung

- Malignant pleural effusion

2. General Medical Exclusions

- Surgical candidates

- Patients who are pregnant at the time of diagnosis

- Serious concomitant systemic disorders incompatible with the study

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 12 weeks

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study

- Patients with septicemia or severe infection.

- Patients who have circumstances that will not permit completion of this study or
the required follow-up

- Patients with any contraindication to gemcitabine, carboplatin, or paclitaxel